Preclinical Studies Support CBD for Cognitive Impairment, but Human Evidence Is Still Missing
A narrative review found preclinical studies consistently support CBD improving cognition, but clinical human evidence has not yet confirmed these effects.
Quick Facts
What This Study Found
Preclinical studies demonstrated CBD improved cognitive performance in animal models of schizophrenia, epilepsy, Alzheimer's, and others. Clinical studies have not found consistent evidence. More research is needed.
Key Numbers
Preclinical evidence positive across multiple disease models. Clinical evidence not consistently supportive.
How They Did This
Narrative review evaluating preclinical and clinical data on CBD for cognitive impairment across multiple disorders.
Why This Research Matters
Cognitive impairment is a major component of many disorders and is often treatment-resistant. The failure to translate animal CBD findings to humans is a critical gap.
The Bigger Picture
The translation gap between animal and human CBD studies is a recurring theme in cannabinoid research.
What This Study Doesn't Tell Us
Narrative review without meta-analysis. Limited clinical studies. Varying assessment tools and doses.
Questions This Raises
- ?Are current clinical trial designs adequate to detect CBD cognitive effects?
- ?Would chronic CBD show cognitive benefits that acute dosing does not?
Trust & Context
- Key Stat:
- Animal studies support CBD for cognition, but human trials have not confirmed it
- Evidence Grade:
- Narrative review highlighting a clear translational gap.
- Study Age:
- Published 2023.
- Original Title:
- Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.
- Published In:
- Experimental and clinical psychopharmacology, 31(5), 978-988 (2023)
- Authors:
- Ortiz, Rachel, Rueda, Sergio(8), Di Ciano, Patricia(10)
- Database ID:
- RTHC-04826
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can CBD improve cognitive function?
Animal studies suggest it can, but human trials have not confirmed cognitive benefits.
What conditions were studied?
Schizophrenia, epilepsy, Alzheimer's disease, and other conditions.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04826APA
Ortiz, Rachel; Rueda, Sergio; Di Ciano, Patricia. (2023). Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.. Experimental and clinical psychopharmacology, 31(5), 978-988. https://doi.org/10.1037/pha0000659
MLA
Ortiz, Rachel, et al. "Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.." Experimental and clinical psychopharmacology, 2023. https://doi.org/10.1037/pha0000659
RethinkTHC
RethinkTHC Research Database. "Use of cannabidiol (CBD) for the treatment of cognitive impa..." RTHC-04826. Retrieved from https://rethinkthc.com/research/ortiz-2023-use-of-cannabidiol-cbd
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.